Resumen
Background: The ISARIC prospective multinational observational study is the largest cohort of hospitalized patients with COVID-19. We present relationships of age, sex, and nationality to presenting symptoms. Methods: International, prospective observational study of 60 109 hospitalized symptomatic patients with laboratory-confirmed COVID-19 recruited from 43 countries between 30 January and 3 August 2020. Logistic regression was performed to evaluate relationships of age and sex to published COVID-19 case definitions and the most commonly reported symptoms. Results: ‘Typical’ symptoms of fever (69%), cough (68%) and shortness of breath (66%) were the most commonly reported. 92% of patients experienced at least one of these. Prevalence of typical symptoms was greatest in 30- to 60-year-olds (respectively 80, 79, 69%; at least one 95%). They were reported less frequently in children (≤ 18 years: 69, 48, 23; 85%), older adults (≥ 70 years: 61, 62, 65; 90%), and women (66, 66, 64; 90%; vs. men 71, 70, 67; 93%, each P < 0.001). The most common atypical presentations under 60 years of age were nausea and vomiting and abdominal pain, and over 60 years was confusion. Regression models showed significant differences in symptoms with sex, age and country. Interpretation: This international collaboration has allowed us to report reliable symptom data from the largest cohort of patients admitted to hospital with COVID-19. Adults over 60 and children admitted to hospital with COVID-19 are less likely to present with typical symptoms. Nausea and vomiting are common atypical presentations under 30 years. Confusion is a frequent atypical presentation of COVID-19 in adults over 60 years. Women are less likely to experience typical symptoms than men.
Idioma original | Inglés |
---|---|
Páginas (desde-hasta) | 889-905 |
Número de páginas | 17 |
Publicación | Infection |
Volumen | 49 |
N.º | 5 |
DOI | |
Estado | Publicada - 25 jun. 2021 |
Nota bibliográfica
Publisher Copyright:© 2021, The Author(s).
Financiación
Financiadores | Número del financiador |
---|---|
EU Platform for European Preparedness Against | |
HPRU | |
Irish Critical Care Trials Group | |
McGill Interdisciplinary Initiative in Infection and Immunity | |
NIHR Biomedical Research Centre at Imperial College London | IS-BRC-1215-20013 |
National Institutes of Health | |
Bill and Melinda Gates Foundation | OPP1209135 |
Astellas Pharma US | |
GlaxoSmithKline | |
Merck | |
Roche | |
Procter and Gamble | |
Baxter International | |
Gilead Sciences | |
National Center for Advancing Translational Sciences | UL1TR002240 |
Boehringer Ingelheim | |
Merck Sharp and Dohme | |
Wellcome Trust | 215091/Z/18/Z |
Seventh Framework Programme | 602525 |
UK Research and Innovation | 2014047.1 |
Gilead UK and Ireland Corporate Contributions | |
Imperial Experimental Cancer Medicine Centre | C18616/A25153 |
National Institute for Health Research Health Protection Research Unit | |
Canadian Institutes of Health Research | OV2170359 |
Medical Research Council | MC_PC_19059 |
National Institute for Health and Care Research | CO-CIN-01 |
Department for International Development, UK Government | |
Imperial College London | 200927 |
Oxford University | 200907 |
Health Research Board | 2014-012 |
Public Health England | |
Norges Forskningsråd | 312780 |
Prince Charles Hospital Foundation |